// App-Quantinova.ai

CT283 : A randomized, double-blind, placebo-controlled, phase 3 study of pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract carcinoma

Researchers

Presenter

  • Richard S. Finn

Principal Investigators

  • Robin K. Kelley

  • Junji Furuse

  • Julien Edeline

  • Zhenggang Ren

  • Shu-Chih Su

  • Usha Malhotra

  • Abby B. Siegel

  • Juan W. Valle

Medical Centers

  • UCLA, Los Angeles, CA

  • UCSF, San Francisco, CA

  • Tokyo University Hospital, Tokyo, Japan

  • Centre Eugene-Marquis, Rennes, France

  • Fudan University, Shanghai, China

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

Locations

  • United States

  • Japan

  • France

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Hepatitis B

  • Hepatitis C

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Gemcitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT04003636

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved